Next Article in Journal
Fulfilling the Potential of Real-World Evidence for Lung Cancer in Canada
Previous Article in Journal
Treatment-Induced Remission of Medulloblastoma Using a Chemotherapeutic Regimen Devoid of Vincristine in a Child with Charcot–Marie–Tooth Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 2
10.3747/co.26.4377
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung

by
C. Roesel
1,*,
K. Kambartel
2,
U. Kopeika
1,
A. Berzins
1,
T. Voshaar
2 and
T. Krbek
1
1
Department for Thoracic Surgery, Lung Cancer Center, Bethanien Hospital, Moers, Germany
2
Department of Pneumology and Allergy, Lung Cancer Center, Bethanien Hospital, Moers, Germany
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(2), 270-273; https://doi.org/10.3747/co.26.4377
Submission received: 9 January 2019 / Revised: 3 February 2019 / Accepted: 3 March 2019 / Published: 1 April 2019

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung carcinoma with a poor prognosis and poor response to chemotherapy and radiotherapy. A previous study reported that psc expresses high levels of PD-L1, suggesting the potential efficacy of immune checkpoint inhibitors in these tumours. We report 2 cases of patients with a lung sarcomatoid carcinoma. Both patients initially underwent curative lung resection, but developed early recurrent disease. Because PD-L1 was highly expressed in the tumour cells, we initiated therapy with nivolumab, which showed good efficacy, almost complete radiologic tumour remission, and a remarkable improvement in the condition of those patients. Immune checkpoint inhibitors targeting PD-1 might be a valuable therapy option for PSCS.
Keywords: sarcomatoid carcinoma; lung cancer; immunotherapy; PD-L1 expression sarcomatoid carcinoma; lung cancer; immunotherapy; PD-L1 expression

Share and Cite

MDPI and ACS Style

Roesel, C.; Kambartel, K.; Kopeika, U.; Berzins, A.; Voshaar, T.; Krbek, T. Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung. Curr. Oncol. 2019, 26, 270-273. https://doi.org/10.3747/co.26.4377

AMA Style

Roesel C, Kambartel K, Kopeika U, Berzins A, Voshaar T, Krbek T. Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung. Current Oncology. 2019; 26(2):270-273. https://doi.org/10.3747/co.26.4377

Chicago/Turabian Style

Roesel, C., K. Kambartel, U. Kopeika, A. Berzins, T. Voshaar, and T. Krbek. 2019. "Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung" Current Oncology 26, no. 2: 270-273. https://doi.org/10.3747/co.26.4377

APA Style

Roesel, C., Kambartel, K., Kopeika, U., Berzins, A., Voshaar, T., & Krbek, T. (2019). Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung. Current Oncology, 26(2), 270-273. https://doi.org/10.3747/co.26.4377

Article Metrics

Back to TopTop